

## Armour Pharmaceutical Company Limited


E0000018/1

St. Leonards House, St. Leonards Road, Eastbourne, Sussex BN213YG Telephone: Eastbourne (0323) 21422 Telex: GRO-C

RBC/EB

June 4, 1985

Dr. Ishmael, Consultant Haematologist, Morriston Hospital, Morriston, Swansea, SA6 6NL.



## RE: HEAT TREATED FACTORATE BATCH NO. Y69402

Further to Mr. Bishop's letter of 10th May, we have been advised by the Department of Health that they would be very interested if all patients who have received this batch of material could be followed up for HTLV-III antibody conversion and/or any clinical or haematological signs of AIDS or pre-AIDS symptomology.

They would also like to know the numbers of patients who received this particular batch of material.

It would be extremely helpful if you could assist in this matter in the following way:

- (i) Provide the number of patients who received Factorate batch Y69402, the dose and the number of separate occasions that the product was administered to individual patients.
- (ii) If known, the HTLV-III antibody status of these patients prior to receiving
- (iii) The patient's clinical condition and immunological status prior to receiving
- (iv) The patient's current HTLV-III antibody status, and clinical condition, T4

	T8 lymphocyte ratio, etc., and then a follow-up at intervals for two years.	appr	roximately six mon	th	
	All information will be treated in the strictest confidence identify patients by name.	and	it is not necessary	to	
		Cont'd			
EV166	Registered Office: St. Leonards House, St. Leonards Road, Eastbourne, Sussex BN:	c:	Mr. C.J. Collins Mr. C. Bishop	2483	

I realise that this request imposes an additional burden on your unit, but it is an unusual opportunity to assess the effectiveness of heat treatment in rendering a batch of Factor VIII safe which was known to contain plasma from a donor who has developed AIDS.

/Your kind assistance would be much appreciated. If we can help in any way, please let me know. We are making a similar request to the other centres who received the batch in question.

Kind regards,

Yours sincerely,

GRO-C

R. B. Christie,

DIRECTOR OF CLINICAL SCIENCES